Tandem integrates, partners with Abbott 

SAN DIEGO – Tandem Diabetes Care has announced that the Tandem t:slimX2 insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor. The company has initiated an early access program in the United States and intends to scale availability in the second half of 2025. “Diabetes management is not one-size-fits-all and it is critical for people living with diabetes to be able to personalize their AID systems to fit their unique healthcare and lifestyle needs,” said Dr. Jordan Pinsker, chief medical officer of Tandem Diabetes Care. “The American Diabetes Association recommends AID systems as the preferred insulin delivery method in people with type 1 and other types of insulin-deficient diabetes, and this integration with Abbott’s latest generation sensor allows even more CGM users to access the life-changing benefits of our Control-IQ+ technology.” Tandem has also announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott’s future dual glucose-ketone sensor with Tandem’s insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to help people living with diabetes detect early ketone rise to avoid life-threatening diabetic ketoacidosis. "Integrating our advanced insulin delivery systems with Abbott’s future glucose-ketone sensor has the potential to help empower people with diabetes to take faster, more informed action to protect their health and improve outcomes," said John Sheridan, president and CEO. "We are excited to continue our partnership with Abbott and look forward to working with them to bring this new integration to customers in the future."